Open label pilot of personalized, neuroimaging-guided theta burst stimulation in early-stage Alzheim...
Open label pilot of personalized, neuroimaging-guided theta burst stimulation in early-stage Alzheimer's disease
About this item
Full title
Author / Creator
Publisher
Switzerland: Frontiers Media S.A
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: Frontiers Media S.A
Subjects
More information
Scope and Contents
Contents
Alzheimer's disease (AD) is characterized by cerebral amyloid plaques and neurofibrillary tangles and disruption of large-scale brain networks (LSBNs). Transcranial magnetic stimulation (TMS) has emerged as a potential non-invasive AD treatment that may serve as an adjunct therapy with FDA approved medications.
We conducted a 10-subject open label, single site study evaluating the effect of functional connectivity-resting state functional MRI guided-approach to TMS targeting with dysfunctional LSBNs in subjects with biomarker-confirmed early-stage AD (https://clinicaltrials.gov/study/NCT05292222). Subjects underwent pre-post imaging and testing to assess connectivity dysfunction and cognition. All participants received intermittent theta burst stimulation [(iTBS), (80% motor threshold; 5 sessions per day; 5 days; 3 targets; 18,000 pulses/day)] over 2 weeks. Three Human Connectome Project (HCP) defined parcellations were targeted, with...
Alternative Titles
Full title
Open label pilot of personalized, neuroimaging-guided theta burst stimulation in early-stage Alzheimer's disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_72a868ca11ff408e8e5edc1812d16a70
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_72a868ca11ff408e8e5edc1812d16a70
Other Identifiers
ISSN
1662-4548,1662-453X
E-ISSN
1662-453X
DOI
10.3389/fnins.2024.1492428
